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Supplementary Figure 2 -SDS-PAGE analysis: Optimization of homodimer yield using varying equivalents of BDBM(PEG) 19 .
Optimizing yield of scFv homodimer by varying equivalents of linker BDBM(PEG) 19 . Lane 1; Reduced scFv. Lane 2; scFv + 0.42 equiv. BDBM(PEG) 19 . Lane 3; scFv + 0.5 equiv. BDBM(PEG) 19 . Lane 4; scFv + 1.0 equiv. BDBM(PEG) 19 . Lane 5; scFv + 2.0 equiv. BDBM(PEG) 19 . 
scFv-linker
MALDI spectrum of scFv-Fab was attempted, however good peak resolution could not be achieved using the facilities available. 
Supplementary Methods

General Methods
Unless otherwise specified, all reagents were purchased from Sigma-Aldrich and used without further purification. Anti-CEA ds-scFv was kindly provided by Dr Berend Tolner, UCL Cancer
Institute and produced as previously described (1 Coupling constants (J values) are reported in Hertz (Hz) and are H-H coupling constants unless otherwise stated. Infra-red spectra were recorded on a PerkinElmer Spectrum 100 FT-IR spectrometer operating in ATR mode with frequencies given in reciprocal centimetres (cm -1 ).
High resolution mass data were obtained by the EPSRC UK National Mass Spectrometry Facility (NMSF), Swansea. MALDI-TOF analysis was performed on a MALDI micro MX (Micromass)
by Dr Kersti Karu (UCL Mass Spectrometry Service). Melting points were measured on a Gallenkamp heating block and are not corrected. All reactions were performed in an inert-gas environment if not stated otherwise. All buffer solutions were filter-sterilised.
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Trastuzumab Fab Fragment Preparation
Trastuzumab Fab was prepared by the sequential digest protocol as described previously (2).
Protocol for CEA ELISA
ELISA plates were coated with full length human CEA diluted to a final concentration of 1 µg/ ml in PBS and incubated for 1 h at room temperature. After washing with PBS, the plates were blocked for 1 h at room temperature with a 5% solution of Marvel milk powder in PBS (Premier 
Cell Lines
The breast cancer cell lines BT474 and MDA-MB-468 were purchased from ATCC. The A375CEA was generated by stable transfection of the A375 melanoma cell line (ATCC); in brief, A375 cells were transfected with pIRES-puro-CEA (kind gift of Dr. David Gilham) and stable clones selected using 1µg/ml of puromycin (Sigma) over a period of two weeks.
A375CEA and MDA-MB-468 cell lines were maintained at 37˚C, 5% CO 2 in Dulbecco's Modified Eagle's Medium (DMEM, Gibco) containing 2mM L-glutamine and complemented with 10% foetal calf serum (Labtech International, UK). BT474 cells were maintained in Hybricare X-46 (ATCC), supplemented with 10% foetal calf serum.
Flow cytometry analysis
Cell lines were prepared by removal of media and incubation with 10 ml of 0.2% EDTA for 10 min. The cells were then transferred to centrifuge tubes and pelleted (4 °C, 4 min, 1000 rpm).
The EDTA solution was removed and 5 ml of fresh media added. Cells were counted and diluted to 1 million per ml, and 1 ml used for each condition to be tested. After washing with cold PBS, 
